The future of microfluidics for biomarker detection
What are the recent advances in forensic oral fluid bioanalysis?
MS shows potential to be applied in surgical procedures
Metabolite demonstrated to correlate with age
Technology companies to collaborate over diagnostics development
Diagnostic company and stable isotope manufacturer form biomarker alliance
Bioinformatics company to support biomarker research of biopharmaceutical group
▪ Vaughn Miller, Agilent Technologies, Wakefield, MA, USA vaughn.miller@agilent.com
▪ Ronald Shoup, AIT Bioscience, LLC, IN, USA rshoup@aitbioscience.com
▪ Matthew Szapacs, GlaxoSmithKline, Drug Metabolism & PK, King of Prussia, PA, USA matthew.e.szapacs@gsk.com
▪ Jin Wang, Amgen, Inc., CA, USA jinw@amgen.com
Long Yuan, Bristol-Myers Squibb, Princeton, NJ, USA long.yuan@bms.com
▪ Joseph Tweed, Pfizer, Inc., Groton, CT, USA joseph.tweed@pfizer.com
Bioanalytical outsourcing: the two sides of the medal
Evaluation and subsequent minimization of matrix effects caused by phospholipids in LC–MS analysis of biological samples
Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC–HRMS and untargeted data processing
Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium
IS addition in bioanalysis of DBS: results from the EBF DBS-microsampling consortium
The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium
In-depth study of homogeneity in DBS using two different techniques: results from the EBF DBS-microsampling consortium
Dried blood spots in bioanalysis of antimalarials: relevance and challenges in quantitative assessment of antimalarial drugs
State-of-the-art dried blood spot analysis: an overview of recent advances and future trends